Metraipolis › archive › dc_5384b4e03e24

TP53-mutated MDS and AML: immune dysregulation, tumor microenvironment, and emerging therapeutic strategies — Europe PMC PMID:40909943

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/40909943
DOI
10.3389/fonc.2025.1655486
License (as archived)
solo-consultazione
Archived
2026-11-10T11:47:02.114Z
SHA-256 of the archived text
5cb9e815c91efb2d5b0cf1bf7d6e6b48cbc993fba1ffe3d5925bec3921202c9a
Stable URL of this page
https://metraipolis.com/documento/dc_5384b4e03e24

How to cite

TP53-mutated MDS and AML: immune dysregulation, tumor microenvironment, and emerging therapeutic strategies — Europe PMC PMID:40909943 — Europe PMC (en), https://europepmc.org/article/MED/40909943 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_5384b4e03e24 (Metraipolis archive dc_5384b4e03e24, sha256 5cb9e815c91efb2d5b0cf1bf7d6e6b48cbc993fba1ffe3d5925bec3921202c9a)
BibTeX
@misc{dc5384b4e03e24,
  title = {TP53-mutated MDS and AML: immune dysregulation, tumor microenvironment, and emerging therapeutic strategies — Europe PMC PMID:40909943},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/40909943},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_5384b4e03e24; sha256 5cb9e815c91efb2d5b0cf1bf7d6e6b48cbc993fba1ffe3d5925bec3921202c9a},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40909943. Agents can read the archived copy with the MCP tool read_document.